Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another W for you (lol).
My five year old just asked if we could get a dog. I told him “we will discuss this further when the 10Q becomes available.”
Now he wants to know when the 10Q will be available.
Kids these days. Never satisfied.
Not sure why I’m laughing, considering the amount of $ I have in this...
It is possible that they may miss this crazy run since they’re in a lock up period after the IPO in late September.
Getting a 998% return in one day on stellar phase 2 trial results is easier to do when one starts with a $62 million market cap.
The market cap is now $686 million.
The company claims a potential $5 billion market somewhere on their website. If this is true for their drug G2P, the stock seems undervalued, even with the prospect of a future phase 3 trial that might not live up to expectations.
The yahoo finance headline before the market opened this morning certainly helped: “Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer.”
0% recurrence after five years looks like a cure for breast cancer at first glance. Another way to say it is 100% recurrence free after 5 years (Bare with me.)
A few factors take some of the sheen off this headline. First, the above results only apply to Her2+ breast cancers, which are 25% of the BC population.
Second, treatment with Herceptin alone, without the synergy supplied by their drug G2P, results in 89% of patients being recurrence free. While going from 89% to 100% recurrence free is a major development that I in no way want to diminish, it doesn’t have the same impact as the headline in the story.
Third, for the 75% of breast cancers that are Her2-, their G2P drug had zero impact on 5 year recurrence-free rates, which remained at 76%.
Side note: Breast cancer is notorious for recurring up to 20 years later, so the 5 year metric doesn’t hold as much weight as it does with GBM or lung cancer.
Fourth, the p value was 0.0338, which is statistically significant but with such a headline one might expect p=0.0001.
Fifth, a multi year phase 3 trial hasn’t begun, which means a long time before any meaningful news hits again, though I suppose there might be speculation on partnering or buyout.
Sixth, I don’t see a pipeline, which also affects news flow and valuation.
All of the above is provided for context in interpreting the over simplified headline. I’m adding the stock to my watch list and may invest in the future, depending on how things evolve.
Kind of amazing that a 2 month extension of PFS translated into a doubling of 5 year survival. Not aware of those kind of results with other therapies, though my exposure is mainly limited to BC, and that years ago.
Recently published five-year data on Keytruda in Non-small cell lung cancer patients:
Nope, Rocky is a friendly. However, I do believe a certain Miss Palin got out of a math test in 6th grade because she saw Boris and Natasha hiding behind the hydrangeas in her front yard.
That pretty much sums it up with regard to recent price action.
The fact that we are still in an uptrend is positive, as far as that goes.
Ultimately, investors are looking at a binary event while traders jump from one short-term opportunity to the next.
One just never knows what the next moment will bring after rolling out of bed.
Thanks for sharing!
Moose in the front yard is a legitimate excuse to miss the school bus in Alaska. Sounds quaint to city folk.
One source to check is Morningstar’s Stewardship ratings. It’s possible to search for “Exemplary” companies, which is a good idea. However, their evaluations tend toward larger market caps so early stage companies are unlikely to show up.
I believe a free trial is available.
Thanks Senti for posting this story—somehow missed it through the years.
Evaluate, appreciate the effort on getting the link!
“When the lawless men eventually realized that his body could not be consumed by fire, they ordered an executioner to go up to him with a dagger. And when he did this, there came out a dove and a large quantity of blood, so that it extinguished the fire; and the whole crowd was amazed that there should be so great a difference between the unbelievers and the elect.”
Martyrdom of Polycarp, 16:1
Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting (ASH)
Quick summaries on roughly 16 drugs with results to be shared ASH over the next few days (including times of presentations). Companies mentioned include Crispr, Trillium, Fate, Allogene, Regeneron, Bluebird, Forma, IGM Biosciences, Uniquire, Legend, Constellation, Gilead, Amgen, JNJ, Syndax, Seagen, Takada, Incyte,
https://finance.yahoo.com/news/red-hot-biotechs-center-stage-171054032.html
Yep Cap’n, since the trajectory of three of the bullets passed through Jules, good luck isn’t the answer.
The only other possibility it seems, besides the miraculous, is that the whole thing was an elaborate, convoluted magic trick orchestrated by Marsellus. He could have recruited the guy in the bathroom to kill Jules and Vincent, given him the gun loaded with blanks and rigged the room with special effects to reveal bullet holes in the walls, the revelation of the holes triggered by the specific noise signature of the “hand cannon.” But there’s zero evidence for any of that.
By coincidence, I happened to read the story of Cain and Abel recently and made the connection to Caine in the TV show Kung Fu, and so to Jules. After Cain murdered Abel, he was condemned to be a restless wanderer on the earth.
And to think this was inspired as a response to feeble attacks on the two Lindas.
Yep. Reminds me of the scene in Pulp Fiction where the guy charges out of the bathroom, gun blazing. In this case, the two Linda’s are surrounded by bullet holes in the wall, unscathed. As you suggest, there is another possible explanation besides good luck or divine intervention.
In any case, it was something to behold.
Agreed — likely direction is up in the very near term.
Final toss of my $1.60 (minimum) spaghetti noodle, sticking to the wall tomorrow.
(But definitely by the time the price kisses the beautiful curve).
Nope, just the same noodle (at least $1.60) tossed twice (“tomorrow” on Monday evening, “by the end of this week” since then).
What there is a lot of on the floor is chicken entrails. I’m going old school.
It looks like that scene in “The Meaning of Life” where the two guys come to claim the liver donation.
Still predicting at least $1.60 by end of week (though probably will happen tomorrow).
Predict early and often!
In the spirit of predicting often, I predict at least $1.60 before the end of the week.
Well, you get a gold star for coming up with something interesting!
Makes one wonder about the status of the frogs...
I’ve got a little side bet of (at least) $1.60 tomorrow. Fingers crossed.
Probably not an economist — they’re known for qualifying their statements so that they cancel out: “It looks like the economy will grow by x. On the other hand...”
I believe it was a past president who said — “Find me a one-handed economist!”
Dang, I have to hit the restroom — I hope the show doesn’t start before I get back!
Just kidding DL. I’ve committed to sitting here until the show is over. Hoping I don’t wet my pants!
Lykiri, you are absolutely killing it on DD. Appreciate your work!
Excellent— better to avoid going through google whenever possible. One of my minions sent me the article with the google link, and I just passed it on as is.
Mr Mountain, I’d like you to meet Mr Molehill. He’s looking for a model for his next art project.
That is a classic bottom! Agree the $2+ range makes sense pre-TLD.
Good one, Oilpatch! And so very true.
Yes, under the right circumstances, stocks can go up significantly on capital raises.
FATE, a crazy innovative immuno-oncology company using highly engineered stem cells to produce NK cells and T-cells, issued 6.2 million shares at $28.31 (the closing price on 6/8). A 7.7% dilution but raised $175.5 million to push forward their burgeoning pipeline in what is one of the most competitive niches is the market. Time to make hay.
It opened the next day at $29.70, hit a high of $35.77 and closed at $32.72, for a 15.6% gain. The open price was essentially the low price since then. It is currently trading at $48.
It is up 240% in the last year, sitting at a $4.2 billion market cap. In terms of trial results, they’ve treated and reported less than a handful of patients in a phase 1 trial but saw some extremely positive responses.
Unless they have a cure for cancer.
You really should stick to mega cap stocks where the ambiguity has been wrung out.